Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Not applicable Interventional Accepts healthy volunteers Results available

Hybrid Effectiveness-Implementation Study to Improve Clopidogrel Adherence

ClinicalTrials.gov ID: NCT01609842

Public ClinicalTrials.gov record NCT01609842. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 3:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Percutaneous coronary intervention (PCI) is a common invasive cardiovascular procedure performed in the VA with over 13,000 procedures in FY10. Clopidogrel is a critical adjuvant therapy following PCI with stent placement and is generally recommended for up to 1 year following the procedure. Despite the evidence supporting clopidogrel use, studies both outside and within the VA suggest that poor adherence to clopidogrel is common. However, prior interventions targeting non-adherence have not specifically focused on clopidogrel adherence among PCI patients. There are many potential reasons for early clopidogrel discontinuation that involve patient and healthcare system factors. Patients reported the following reasons for discontinuing clopidogrel within 1 month after drug-eluting stent (DES) implantation: 1) misunderstanding the intended treatment duration; 2) conflicting recommendations about intended duration; 3) cost of the medication; and 4) patients' own decision to stop. In contrast, patients who continued to take clopidogrel reported the following as helpful: 1) communication such as letters from their physician; and 2) receiving specific instructions on clopidogrel use. These findings suggest that there are specific interventions that can be implemented to improve clopidogrel adherence. Multi-modal interventions that incorporate frequent follow-up, especially with pharmacists and use interactive voice response (IVR) technology have improved medication adherence. IVR technology is a computer-based telephone system which initiates calls, receives calls, provides information, and collects data from users. IVR is currently a mainstay in the VA where patients frequently interact with these automated systems to get clinic appointments and/or refill prescriptions. IVR as part of multi-modal interventions have been well received by patients, increased adherence to medications (e.g., statins), and improved clinical outcomes (e.g., blood pressure, diabetes symptoms, health status). In addition, the investigators have successfully used IVR as part of a multi-modal, multi-site intervention including pharmacists to improve blood pressure levels among hypertensive patients. Accordingly, the investigators have designed the intervention to improve clopidogrel adherence that builds on the investigators' prior work and other successful adherence interventions from the literature. The investigators propose a hybrid effectiveness-implementation study of a multi-faceted intervention to improve clopidogrel adherence at VA PCI centers. The investigators will use the VA's Cardiovascular Assessment Reporting and Tracking (CART-CL), a uniform cath lab procedure reporting tool at all VA cath labs. The intervention consists of 4 components: a) an alert from CART-CL will be sent to an inpatient pharmacist prior to discharge that a patient has received a stent; b) a pharmacist will bring clopidogrel to the patient's bedside prior to hospital discharge as well as educate the patient on the importance of and adherence to clopidogrel following PCI; c) interactive voice response (IVR) calls will be made to patients prior to the time of clopidogrel refill to remind patients and to facilitate refills during follow-up; and d) a Patient Aligned Care Team (PACT) member will contact patients who delay filling clopidogrel.

Study identification

NCT ID
NCT01609842
Recruitment status
Completed
Study type
Interventional
Phase
Not applicable
Enrollment
14,573 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years to 91 Years
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 19, 2014
Primary completion
Feb 28, 2018
Completion
Feb 6, 2022
Last update posted
Jul 20, 2023

2014 – 2022

United States locations

U.S. sites
15
U.S. states
14
U.S. cities
15
Facility City State ZIP Site status
Rocky Mountain Regional VA Medical Center, Aurora, CO Aurora Colorado 80045
Washington DC VA Medical Center, Washington, DC Washington D.C. District of Columbia 20422
North Florida/South Georgia Veterans Health System, Gainesville, FL Gainesville Florida 32608
Atlanta VA Medical and Rehab Center, Decatur, GA Decatur Georgia 30033
Iowa City VA Health Care System, Iowa City, IA Iowa City Iowa 52246-2208
VA Ann Arbor Healthcare System, Ann Arbor, MI Ann Arbor Michigan 48105
G.V. (Sonny) Montgomery VA Medical Center, Jackson, MS Jackson Mississippi 39216
New Mexico VA Health Care System, Albuquerque, NM Albuquerque New Mexico 87108-5153
Manhattan Campus of the VA NY Harbor Healthcare System, New York, NY New York New York 10010
Durham VA Medical Center, Durham, NC Durham North Carolina 27705
Cincinnati VA Medical Center, Cincinnati, OH Cincinnati Ohio 45220
Louis Stokes VA Medical Center, Cleveland, OH Cleveland Ohio 44106
Oklahoma City VA Medical Center, Oklahoma City, OK Oklahoma City Oklahoma 73104
Michael E. DeBakey VA Medical Center, Houston, TX Houston Texas 77030
Salem VA Medical Center, Salem, VA Salem Virginia 24153

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01609842, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 20, 2023 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01609842 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →